As the first line of defense against the innate response, the complement system could recognize and mediate the process of pathogens, debris, and dead cells removal to protect the human organism; hence, therapies targeting complement C3 still need to be considered carefully in AMD patients [55, 59]. This evidence concerns the gene C3 and age-related macular degeneration.